Intellia Therapeutics (NTLA) Receivables - Other (2016 - 2023)
Historic Receivables - Other for Intellia Therapeutics (NTLA) over the last 9 years, with Q4 2023 value amounting to $1.0 million.
- Intellia Therapeutics' Receivables - Other fell 3750.0% to $1.0 million in Q4 2023 from the same period last year, while for Dec 2023 it was $1.0 million, marking a year-over-year decrease of 3750.0%. This contributed to the annual value of $1.0 million for FY2023, which is 3750.0% down from last year.
- Latest data reveals that Intellia Therapeutics reported Receivables - Other of $1.0 million as of Q4 2023, which was down 3750.0% from $1.0 million recorded in Q3 2023.
- Over the past 5 years, Intellia Therapeutics' Receivables - Other peaked at $8.4 million during Q1 2020, and registered a low of $100000.0 during Q4 2021.
- Its 5-year average for Receivables - Other is $1.8 million, with a median of $1.0 million in 2019.
- Its Receivables - Other has fluctuated over the past 5 years, first tumbled by 8809.52% in 2021, then soared by 150000.0% in 2022.
- Over the past 5 years, Intellia Therapeutics' Receivables - Other (Quarter) stood at $3.6 million in 2019, then plummeted by 66.67% to $1.2 million in 2020, then tumbled by 91.67% to $100000.0 in 2021, then surged by 1500.0% to $1.6 million in 2022, then plummeted by 37.5% to $1.0 million in 2023.
- Its Receivables - Other was $1.0 million in Q4 2023, compared to $1.0 million in Q3 2023 and $1.4 million in Q2 2023.